EUVIMEDEUVIMED entdecken
Vergleichsstudie

Alemtuzumab Induction Reduces Early Rejection in Female Renal Allograft Recipients: A Single Center Study

Jonathan Demeter, Bradley Buck, Allison Zimmerman, Graham Mitro, Michael Rees, Jorge Ortiz

Experimental and Clinical Transplantation · 2019-12 · 17 (6) · 739-748

DOI: 10.6002/ect.2017.0225 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Experimental and Clinical Transplantation, 2019-12. Verfasst von Jonathan Demeter und 5 weiteren Autor:innen. Beteiligte Einrichtung: From the Department of Urology, University of Toledo, College of Medicine and Life Sciences, Toledo, Ohio, USA. Hauptthemen laut MEDLINE: Health Status Disparities, Kidney Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 40 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: Previous research studies have highlighted differences in rejection and graft survival across sexes that favor men. We compared delayed graft function, rejection, graft survival, and overall patient survival between sexes following alemtuzumab induction. MATERIALS AND METHODS: After Internal Review Board approval, a retrospective analysis of kidney transplants completed at the University of Toledo Medical Center between March 2004 and November 2015 was conducted. RESULTS: During the study period, 675 transplants were performed. This included 429 male patients (63.6%) and 246 female patients (36.4%). Recipient sex was not associated with delayed graft function. Acute rejection occurred less frequently in women than in men at 3 months (12.6% vs 20.7%; P = .009) and at 6 months (15.9% vs 24.6%; P = .008). Cumulative patient survival was superior in women (P = .032). Female recipient death-censored graft survival was inferior at 3 years (85.4% vs 91.6%; P = .034) and at 5 years (77.7% vs 86.9%; P = .019) versus male patients. CONCLUSIONS: Compared with men, early female rejection is reduced and overall female survival is longer after alemtuzumab induction. However, intermediate-term female graft survival is less.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Health Status DisparitiesKidney TransplantationAlemtuzumabFemaleGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsMaleOhioRetrospective StudiesRisk AssessmentRisk FactorsSex FactorsTime FactorsTreatment Outcome

Substanzen

Immunosuppressive AgentsAlemtuzumab

Autor:innen und Institutionen

  • From the Department of Urology, University of Toledo, College of Medicine and Life Sciences, Toledo, Ohio, USA.

Zitieren

APA

Demeter, J., Buck, B., Zimmerman, A., Mitro, G., Rees, M., & Ortiz, J. (2019). Alemtuzumab Induction Reduces Early Rejection in Female Renal Allograft Recipients: A Single Center Study. Experimental and Clinical Transplantation, 17(6), 739-748. https://doi.org/10.6002/ect.2017.0225

Vancouver

Demeter J, Buck B, Zimmerman A, Mitro G, Rees M, Ortiz J. Alemtuzumab Induction Reduces Early Rejection in Female Renal Allograft Recipients: A Single Center Study. Experimental and Clinical Transplantation. 2019;17(6):739-748. doi:10.6002/ect.2017.0225

BibTeX
@article{Demeter2019,
  author = {Demeter, Jonathan and Buck, Bradley and Zimmerman, Allison and Mitro, Graham and Rees, Michael and Ortiz, Jorge},
  title = {Alemtuzumab Induction Reduces Early Rejection in Female Renal Allograft Recipients: A Single Center Study},
  journal = {Experimental and Clinical Transplantation},
  year = {2019},
  volume = {17},
  number = {6},
  pages = {739--748},
  doi = {10.6002/ect.2017.0225}
}
Kostenlos starten →